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Introduction 
Streptococcus pneumoniae is considerd a major health problem worldwide, being a cause 
of high morbidity and mortality, especially among infants and elderly subjects [1]. In 
Europe, during the pre-vaccination era, about 260,000 episodes of serious pneumococcal 
diseases were estimated to occur yearly among children aged 1-59 months [2]. Since 
2007, the World Health Organization (WHO) has recommended the worldwide introduc-
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SUMMARY 
Purpose: Aim of this study was to analyze pediatric invasive pneumococcal disease rates 
several years after the implementation of infant pneumococcal vaccination.  
Methods: The study was carried out in Sicily and involved about 30,000 children, aged 1-
59 months, actively monitored by 100 family pediatricians during 2010 and 2011. All 
children who met the inclusion criteria were considered eligible, recorded using a stan-
dardized case report form and investigated for the presence of S. pneumoniae in speci-
mens from sterile sites.  
Results: None of the 40 eligible children was confirmed as a case of invasive pneumococ-
cal disease. The incidence rate of invasive pneumococcal disease cases was 0.0/100,000 
in both years. Regional childhood pneumococcal vaccination coverage rates were 90.7% in 
2010 and 92.0% in 2011.  
Conclusions: Our results show that during the study period invasive pneumococcal dis-
ease cases were rare in Sicilian children, suggesting a very effective control of the disease 
in a region with  very high vaccination coverage against S. pneumoniae. 
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tion of the conjugate pneumococcal vacci-
nation into national immunization pro-
grams (NIPs), with the aim of reducing the 
burden of invasive pneumococcal diseases 
(IPD) [3]. Moreover, the WHO has also rec-
ommended appropriate surveillance of IPD, 
by estimating the vaccine coverage rate 
and monitoring the effect of vaccination 
continuously [3]. In Italy, pneumococcal 
vaccination in infants has been recom-
mended since the 2005-2007 national 
immunization program [4]; however, in 
Sicily, universal infant vaccination with 
pneumococcal conjugate vaccine began in 
2004, with 3 doses at 3, 5 and 11 months. 
Nevertheless, despite the gradual increase 
of vaccine uptake, there is a general lack of 
local data regarding the burden of pediat-
ric IPD after the introduction of the univer-
sal vaccination program.  
In order to contribute to the data support-
ing the effectiveness of pneumococcal 
vaccination in infants, in the present study, 
we analyzed IPD rates in a sample popula-
tion  of children aged less than 5 years in 
Sicily during two years of active surveil-
lance. 
 
Material and methods 
 
Study design 
Prospective, population-based surveillance 
study carried out in all 9 Sicilian districts 
(Agrigento, Caltanissetta, Catania, Enna, 
Messina, Palermo, Ragusa, Siracusa, and 
Trapani) among a pediatric population. An 
active surveillance program was conducted 
from 1st January 2010 to 31st December 
2011 by 100 family pediatricians who were 
willing to participate to the surveillance 
network.  Considering a mean of about 
300 children aged 0-59 months for each 
family pediatrician [5], the surveillance was 
expected to cover a total of about 30,000 
pediatric subjects, accounting for about 
10% of the entire general population aged 
less than 5 years and living in Sicily in 
2010 and 2011 (294,187 and 296,170 
subjects, respectively). Moreover, data on 
regional pneumococcal vaccination cover-
age were obtained from the Health Depart-
ment of the Sicilian government.    
 
Eligible subjects and case definition  
All family pediatricians were well-trained to 
actively assess all patients with clinical 
suspicion of IPD. As a consequence, chil-
dren who met the following inclusion crite-
ria were considered eligible and further 
investigated for IPD: 
- axillary temperature ≥39.0 °C and/or 
clinical suspicion of IPD (as any invasive S. 
pneumoniae syndrome); 
- negative urine analysis for urinary tract 
infections based on fast urine test; 
-  C-reactive protein (CRP) > 15 mg/L. 
The exclusion criterion was refusal of the 
parent or legal guardian to give written 
consent. The role of the family pediatrician 
was to enroll eligible patients and fill in a 
standardized case report form (e-CRF) 
including demographic information, base-
line diagnosis, history of receipt of a conju-
gate or polysaccharide pneumococcal vac-
cine, and absence/presence of factors 
known to be associated with IPD. Finally, 
IPD cases were defined as eligible subjects 
with the isolation of Streptococcus pneu-
moniae, or a positive Polymerase Chain 
Reaction (PCR) test, from a normally sterile 
site [6, 7].  
 
Laboratory analyses  
Upon enrolment, a blood sample was col-
lected. Specimens from other sterile sites 
(pleural, joint, and cerebrospinal fluids) 
were collected as per routine medical prac-
tice. All samples were cultured for bacteria. 
According to the study by protocol, if S. 
pneumonia was detected in a participant, 
antimicrobial susceptibility was tested for 
and a subculture of the isolate was trans-
ferred to the laboratory of the Azienda 
Ospedaliero-Universitaria Policlinico 
“Gaspare Rodolico” in Catania in order to 
perform serotyping using a commercial kit 
for latex agglutination (Pneumotest latex 
kit, Statens Serum Institute, Copenhagen, 
Denmark). Finally, PCR testing was per-
formed on sterile fluids of all subjects who 
met the inclusion criteria. Genomic DNA 
was extracted using the Pure Link RNA 
Mini Kit (Invitrogen) and PCR amplification 
of the lytA and ply genes was used to iden-
tify presumptive S. pneumoniae. 
 
Statistical analysis 
Subjects were enrolled in the study in ac-
cordance with the inclusion and exclusion 
criteria. Absolute and relative frequencies 
were calculated for qualitative variables, 
while quantitative variables were summa-
rized as mean ± standard deviation. Inci-
dence of IPD was estimated by the number 
of laboratory confirmed IPD cases divided 
by the number of children monitored in the 
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sampled population per year. Data were 
analyzed using the R statistical software 
package. 
 
Results 
As reported in table 1, a total of 31,618 
(M/F ratio=1.05; mean age=  23.9 ± 17.8 
months) and 31,109 children (M/F ratio= 
1.04; mean age= 23.4±16.8 months) were 
observed during 2010 and 2011, respec-
tively. The final observed sample ac-
counted for 10.6% of the entire Sicilian 
population aged less than 5 years, ranging 
from 7.3% in Enna to 11.8% in Palermo. 
Figure 1 shows IPD cases and vaccination 
coverage observed during the study pe-
riod. 
Regional pneumococcal vaccination cover-
age rates were 90.7% in 2010 and 92.0% in 
2011.  
During the surveillance period, 40 children 
(23 in 2010, accounting for 0.07% and 17 
in 2011, accounting for 0.05%) met the 
inclusion criteria and were recruited in the 
study. None of the eligible subjects was 
confirmed as an IPD case. The overall inci-
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Figure 1: IPD cases and vaccination coverage observed during the study period.  
Table 1: Characteristics of the pediatric sample population observed during  
the two years of surveillance.  
  
2010 2011 
      
Sample population aged 0-59 months; 
n (% of the entire pediatric Sicilian population) 31,618 (10.7%) 31,109 (10.5%) 
M/F ratio 1.05  1.04 
Age in months; mean ± SD 23.9 ± 17.8 23.4 ± 16.8 
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dence rate of IPD cases was 0.0/100,000 
in both years. 
 
4. Discussion 
Measuring the local burden of vaccine 
preventable disease using active surveil-
lance models is of crucial importance in 
informing policy-makers regarding the 
implementation of evidence-based public 
health strategies such as vaccination cam-
paigns. In Sicily, pneumococcal vaccination 
for infants began in 2004 but, to the best 
of our knowledge, this is the only study 
designed with the aim of evaluating the 
effects of pneumococcal vaccination in the 
reduction of the IPD burden in the pediat-
ric general population. Our results show 
that invasive pneumococcal infections can 
be considered relatively rare in Sicilian 
children, suggesting a very effective re-
gional control of the disease. This result 
was, at least in part, expected for two 
main reasons.  
Firstly, our data seem to represent a trend 
whereby Italian regions with higher pneu-
mococcal vaccination coverage such as 
Sicily (>90%) and Puglia (81.9%) [8] report 
lower IPD incidence rates than regions 
such as Lombardia, where only 27.1% of 
infants were vaccinated against S. pneumo-
niae [8]. Indeed, other Italian studies re-
port IPD rates from 2.8/100,000 per year 
in Puglia and 5.7/100,000 in Piemonte [9], 
but rates of 50.0/100,000 cases per year 
in Lombardia [10].  
Secondly, the total absence of IPD cases in 
our study population is expected since, at 
the beginning of this study, universal 
pneumococcal vaccination of Sicilian in-
fants had already  been in place for more 
than 5 years with very high vaccination 
coverage (> 90%). As a consequence, a 
very large majority of subjects included in 
the surveillance was expected to have 
been vaccinated against pneumococcal 
infection. Moreover, several authors have 
observed a reduction of nasopharyngeal 
carriage of vaccine strains in both vacci-
nated and unvaccinated children after the 
introduction of conjugate pneumococcal 
vaccines [11, 12]. Although the indirect 
effect cannot easily be measured and a 
vaccine induced replacement has been 
reported by some authors [13],  the fact 
that the very high vaccine coverage in our 
study population could have reduced the 
rate of pneumococcal diseases also in non-
immunised individuals as a consequence 
of the herd effect, should be taken into 
consideration.  
Finally, the present study could have some 
limitations due primarily to the relatively 
small number of subjects recruited.  As a 
result, incidence could be significantly 
distorted by changes in the numbers of 
isolates. Moreover, it is not possible to be 
certain that family pediatricians captured 
all potential eligible subjects, which could 
result in a possible underestimation of 
disease burden.   
Despite these possible limitations, the 
present study is the first that estimates IPD 
incidence in an Italian region where pneu-
mococcal vaccination has both been in 
place for a relatively long time and has a 
high coverage. The absence of IPD cases 
during the surveillance period, in compari-
son with higher IPD incidence rates ob-
served in other Italian regions with lower 
pneumococcal vaccination coverage, sug-
gests the importance of maintaining very 
high immunization levels against S. pneu-
moniae.  
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